Pivotal role of xanthine oxidase in the initiation of tubulointerstitial renal injury in rats with hyperlipidemia.
Hyperlipidemia can induce or aggravate renal tubulointerstitial injury. Experiments in a complex rat model with chronic glomerulonephritis and long-standing, coexisting hyperlipidemia suggested that induction of xanthine oxidase (XO), with increased oxygen radical generation, is involved in aggravation of tubulointerstitial injury. To separate the role of XO in the initial events of lipid-mediated tubulointerstitial injury, short-term experiments with diet-induced hyperlipidemia over 21 and 35 days were performed in otherwise healthy rats. XO expression in relation to the antioxidant enzymes was examined in the cortical tubulointerstitium (TIS) and proximal tubules (PT). Subsequent experiments with XO inhibition were performed, examining tubulointerstitial infiltration with ED1-positive cells and expression of adhesion molecules and monocyte chemoattractant protein-1 (MCP-1) as indicators of early injurious events. Hyperlipidemia increased XO activity in TIS by 40 and 86%, and in PT by 28 and 90% at days 21 and 35, compared with controls on regular diet. This increased activity was associated with increased reactive oxygen species. Among the antioxidant enzymes, glutathione peroxidase activity increased in TIS by 40% and in PT by 90%. Histological evaluation showed a three-fold increase in ED1-positive cells and increased MCP-1 and vascular cell adhesion molecule-1 (VCAM-1) expression at day 35 in the TIS. Inhibition of XO prevented tubulointerstitial ED1 cell infiltration, together with a decreased expression of MCP-1 and VCAM-1. These results point to an important role for XO in the early stage of hyperlipidemia-associated renal injury, mediating macrophage infiltration by a putatively redox-dependent upregulation of MCP-1 and VCAM-1.
Gwinner
W
W
Department of Nephrology, Medical School of Hannover, Hannover, Germany. gwinner.wilfried@mh-hannover.de
Scheuer
H
H
Haller
H
H
Brandes
R P
RP
Groene
H-J
HJ
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D015815:Cell Adhesion Molecules / Q000032:analysis / Q000235:genetics / Q000502:physiology; D018932:Chemokine CCL2 / Q000032:analysis / Q000235:genetics / Q000502:physiology; D053331:Ectodysplasins; D005921:Glomerulonephritis / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D006949:Hyperlipidemias / Q000188:drug therapy / Q000503:physiopathology*; D007150:Immunohistochemistry; D007684:Kidney Tubules / Q000737:chemistry / Q000473:pathology / Q000503:physiopathology; D008264:Macrophages / Q000737:chemistry / Q000473:pathology / Q000502:physiology; D008297:Male; D008565:Membrane Proteins / Q000032:analysis; D009395:Nephritis, Interstitial / Q000201:enzymology* / Q000473:pathology / Q000503:physiopathology*; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism; D048069:Tumor Necrosis Factors / Q000032:analysis; D015854:Up-Regulation; D019010:Vascular Cell Adhesion Molecule-1 / Q000032:analysis / Q000235:genetics / Q000502:physiology; D014969:Xanthine Oxidase / Q000032:analysis / Q000235:genetics / Q000502:physiology*
D000975:Antioxidants; C491766:Ccl2 protein, rat; D015815:Cell Adhesion Molecules; D018932:Chemokine CCL2; D053331:Ectodysplasins; D008565:Membrane Proteins; D017382:Reactive Oxygen Species; D048069:Tumor Necrosis Factors; D019010:Vascular Cell Adhesion Molecule-1; D014969:Xanthine Oxidase